Nuevolution to Present at the 18th Annual Rodman & Renshaw Global Investment Conference

Stockholm, 23 August 2016. Nuevolution AB (publ) (NUE.ST), a leading small
molecule drug discovery biotech company, today announced that it will be
presenting at the 18th Annual Rodman & Renshaw Global Investment Conference. The
conference will take place on September 11-13, 2016 at the Lotte New York Palace
Hotel in New York City.

Alex Haahr Gouliaev, CEO of Nuevolution AB (publ), will provide an overview of
the Company’s business during the live presentation on September 13, 2016, at
15:50-16:15 EDT (21:50-22:15 CEST). Mr. Gouliaev and Henrik D. Simonsen, the
company’s CFO, will be available to participate in one-on-one meetings with
investors.

The presentation will be webcast live. To access the webcast, please visit
www.rodmanevents.com or go to the investor relations section of Nuevolution’s
website. The webcast replay will remain available for 90 days following the live
presentation.

If you are an institutional investor, and would like to attend the Company’s
presentation, please click on the following link (www.rodmanevents.com) to
register for the Rodman & Renshaw conference. Once your registration is
confirmed, you will be prompted to log into the conference website to request a
one-on-one meeting with the Company.

In addition, any investors attending the conference that wish to meet with
Nuevolution’s management for a one-on-one meeting can also contact Henrik
Simonsen at hs@nuevolution.com or Anna Baran-Djokovic at abd@nuevolution.com.

For more information, please contact:

Henrik D. Simonsen, CFO

Phone: +45 3913 0947

Email: hs@nuevolution.com

Anna Baran-Djokovic, Investor Relations Manager

Phone: +44 7521 083006

Email: abd@nuevolution.com

About Nuevolution

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company
founded in 2001, headquartered in Copenhagen, Denmark. Nuevolution partners its
proprietary discovery platform and programs with pharmaceutical and
biotechnology companies to seek future benefit of patients in need of novel
medical treatment options. Nuevolution’s internal programs are focused
on therapeutically important targets within inflammation, oncology and immuno
-oncology.

Nuevolution AB (publ) is required to disclose the information provided herein
pursuant to the Securities Markets Act. The information was sent for publication
on Tuesday 23 August 2016, 13:00 (CEST).

Nuevolution AB (publ) is listed at Nasdaq First North Premier in Stockholm,
Sweden (ticker: NUE.ST). Västra Hamnen Corporate Finance AB acts as Certified
Adviser to Nuevolution AB (publ). More information about Nuevolution can be
found on: www.nuevolution.com